Therapeutic Potential of Agmatine in Essential Tremor Through Regulation of Lingo‐1 and Inflammatory Pathways
Brain and Behavior · 2025
DOI: 10.1002/brb3.70241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Zeynab Pirmoradi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran. Hauptthemen laut MEDLINE: Agmatine, Essential Tremor, Disease Models, Animal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kerman University of Medical Sciences.
Abstract (Originalsprache)
Purpose
Essential tremor (ET) is a prevalent movement disorder, yet current therapeutic options remain limited. Emerging evidence implicates leucine‐rich repeat and immunoglobulin‐like domain‐containing protein (Lingo‐1) and neuroinflammation in the pathophysiology of ET. This study aimed to investigate whether agmatine, a biogenic amine neuromodulator attenuates tremors and modulates the expression of Lingo‐1 and proinflammatory markers in a rodent model of ET.
Methods
Tremor was induced in male Swiss Webster mice through intraperitoneal injections of harmaline (10 mg/kg) on Days 1, 3, and 5 of the study. During the same period, agmatine (40 mg/kg) was administered for 5 consecutive days. Behavioral assessments of tremor severity, gait, balance, muscular strength, locomotion, anxiety‐like behavior, and memory were conducted. Moreover, Lingo‐1 and interleukin (IL)‐6 gene expression was examined in the cerebellum using real‐time polymerase chain reaction (RT‐PCR).
Findings
Our findings demonstrated that agmatine administration significantly reduced tremors, ameliorated anxiety‐like behaviors, and attenuated harmaline‐induced locomotor deficits. At the molecular level, agmatine treatment significantly suppressed the overexpression of Lingo‐1 elicited by harmaline. Moreover, IL‐6 expression was attenuated to an extent comparable to control levels.
Conclusions
Collectively, this study provides the first evidence that agmatine dampens tremor severity, improves behavioral outcomes, and modulates key pathways implicated in ET pathogenesis in a rodent model. The ability of agmatine to normalize Lingo‐1 and IL‐6 expression suggests regulation of these pathways could underlie its neuroprotective action. These results suggest promise for agmatine as a prospective therapeutic agent in ET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
- Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran.
- Department of Drug Design and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Physiology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
ORCID-Profile: Mehran Ilaghi
Förderung
- Kerman University of Medical Sciences
Zitieren
APA
Pirmoradi, Z., Esmaili, Z., Nakhaie, M., Kohlmeier, K. A., Shabani, M., Razavinasab, M., & Ilaghi, M. (2025). Therapeutic Potential of Agmatine in Essential Tremor Through Regulation of Lingo‐1 and Inflammatory Pathways. Brain and Behavior. https://doi.org/10.1002/brb3.70241
Vancouver
Pirmoradi Z, Esmaili Z, Nakhaie M, Kohlmeier KA, Shabani M, Razavinasab M, et al. Therapeutic Potential of Agmatine in Essential Tremor Through Regulation of Lingo‐1 and Inflammatory Pathways. Brain and Behavior. 2025. doi:10.1002/brb3.70241
BibTeX
@article{Pirmoradi2025,
author = {Pirmoradi, Zeynab and Esmaili, Zahra and Nakhaie, Mohsen and Kohlmeier, Kristi A and Shabani, Mohammad and Razavinasab, Moazamehosadat and Ilaghi, Mehran},
title = {Therapeutic Potential of Agmatine in Essential Tremor Through Regulation of Lingo‐1 and Inflammatory Pathways},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70241}
}
EUVIMED